Previous studies highlight Carica papaya's dual therapeutic potential for hypertension and type
2 diabetes. Research demonstrates that papaya leaf extracts improve glucose homeostasis in
diabetic models by modulating insulin signaling pathways, such as IRS-1/Akt and IR/GLUT4,
which regulate glucose metabolism (Roy et al., 2022). Additionally, fermented papaya
preparations (FFP) reduce oxidative stress and improve lipid profiles, contributing to
antihypertensive effects (Habtemariam, 2019). In elderly hypertensive patients, papaya
consumption significantly increased the proportion achieving mild blood pressure control from
33.3% to 66.7% (Wahdi & Puspitosari, 2024). Furthermore, papaya leaf extracts lowered blood
glucose and improved lipid parameters in diabetic rats, with studies reporting reductions in total
cholesterol and triglycerides (Airaodion et al., 2019). These findings underscore papaya’s
promise, though clinical trials are needed to validate efficacy and safety in comorbid
populations.
Previous studies highlight Moringa oleifera’s potential in managing hypertension and type 2
diabetes (T2D), with evidence suggesting its dual role in improving blood pressure and glycemic
control. For hypertension, a clinical trial demonstrated that Moringa supplementation
significantly reduced systolic blood pressure from 136.40 mmHg to 123.90 mmHg, attributed to
its phytochemicals inhibiting pathways linked to vascular dysfunction (Möller, 2023; Chuku et al.,
2019). In T2D, while one trial found no significant fasting blood glucose changes
with Moringa alone (Möller, 2023), co-administration with standard antidiabetic medications
reduced glycemic parameters, such as advanced glycation end products, and improved lipid
profiles by elevating HDL (48.2 mg/dL to 52.1 mg/dL) and lowering LDL (132.5 mg/dL to 118.4
mg/dL) (Nurudeen et al., 2023; Lambe et al., 2024). Additionally, a study using 6g Moringa leaf
capsules reported notable reductions in blood pressure and hyperglycemia in T2D patients
(Mishal Hameed et al., 2024). However, variability in individual responses and insufficient
standardization of dosages underscore the need for further research to validate its efficacy as a
complementary therapy.
Integrated bioinformatics analyses have identified critical hub genes and molecular mechanisms
underlying hypertension, such as RPL21, RPS28, and TBXAS1, which regulate steroid hormone
response and extracellular matrix pathways (Chen et al., 2019; Li et al., 2021). Weighted Gene
Co-expression Network Analysis (WGCNA) revealed 18 hypertension-associated hub genes
(RPS28, FKBP1A) clustered in modules linked to hypoxia-inducible factor (HIF-1) and insulin
signaling pathways (Li et al., 2021), while another study implicated ELK3 in PM2.5-induced lipid
metabolism dysregulation and vascular remodeling (Liu et al., 2023). These hub genes influence
inflammatory responses (e.g., NF-κB signaling) and phenotypic switching in vascular smooth
muscle cells, contributing to hypertension progression (Chen et al., 2019; Liu et al., 2023).
Genome-wide meta-analyses further identified seven key hub genes (ADM, EDN1) enriched in
fatty acid metabolism and MAPK signaling (Ali et al., 2022), with network centrality analyses
highlighting Col4a1 and Lcn2 as statistically significant nodes (Wang et al., 2014). Such findings
underscore the multifactorial interplay of genetic, metabolic, and environmental mechanisms,
offering biomarkers for early diagnosis and therapeutic targeting (Li et al., 2020; Liu et al., 2023).
Previous studies utilizing integrated bioinformatics approaches have identified critical hub genes
and molecular mechanisms in type 2 diabetes (T2D), revealing 925 differentially expressed genes
(DEGs) enriched in pathways like insulin signaling, immune response, and extracellular matrix
organization (Vastrad & Vastrad, 2021; Nematollahi et al., 2024). Key hub genes such
as FN1, JUN, and ERBB2 were consistently linked to cell adhesion and signaling,
with ERBB2 showing tissue-specific dysregulation in pancreatic β-cells (Yadav et al., 2023;
Alshehri, 2024). Functional analyses highlighted the role of miRNAs like hsa-miR-492 in
regulating these genes, suggesting a complex network influencing T2D progression
(Nematollahi et al., 2024). ROC curve analysis (AUC > 0.85) further validated hub genes
like GLUL and SLC32A1 as potential diagnostic biomarkers, while pathway enrichment
implicated oxidative stress (e.g., p53/MAPK pathways) in islet cell apoptosis (Vastrad et al., 2020;
Luo et al., 2024). Despite these insights, the multifactorial nature of T2D—involving genetic,
environmental, and lifestyle factors—necessitates broader integrative models for therapeutic
targeting and personalized interventions.